Mylan Files Suit Against FDA Over Generic Provigil

RELATED NEWS

Trade MYL now with

4/5/2012 2:34 PM ET

Mylan Inc. (MYL: Quote) has filed a lawsuit against U.S Food and Drug Administration, seeking to overturn its decision which awarded Teva Pharmaceutical Industries Ltd. (TEVA: Quote) an 180-days sole exclusivity for the generic version of Cephalon's Provigil.

Provigil is a prescription medicine used to improve wakefulness in adults who experience excessive sleepiness due to sleep disorders. According to IMS Health, Provigil had U.S. sales of about $1.1 billion for the full year ended December 31, 2011.

Mylan's subsidiary, Mylan Pharmaceuticals has filed the suit against FDA in the U.S. District Court for the District of Columbia.

Earlier Thursday, Teva said the FDA decided that its subsidiary Teva Pharmaceuticals USA is the sole first-to-file for both Orange Book patents listed for Provigil, and therefore Teva alone is entitled for the 180-day exclusivity.

Mylan alleged that Teva did not maintain valid paragraph IV (PIV) certifications as a result of its acquisition of Cephalon last year. Mylan's complaint states that after the acquisition of Cephalon, Teva could no longer infringe its own patents and therefore is not entitled to exclusivity based on patent certifications.

Mylan also alleged that FDA should have found that Mylan is the sole first filer on one of the Orange Book Patents for Provigil.

The complaint also says that FDA's decision, which blocks Mylan and other generic entrants from launching their generic Provigil products, is unlawful. Mylan believes the Federal Trade Commission did not contemplate the current outcome when it imposed its conditions on the Teva/Cephalon merger.

Mylan is seeking immediate equitable relief from the Court requiring FDA to approve Mylan's ANDA.

MYL is currently trading on the NYSE at $22.55, down 2.63%, on a volume of 3.6 million shares. TEVA is currently trading at $45.00, up $0.25%, on a volume of 1.36 million shares, on the Nasdaq.

To receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

<<Previous 82 Articles

Editors Pick

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.

Analog Devices Profit Meets Estimate; Outlook Weak

Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates.

Stocks Close Modestly Higher Ahead Of Bernanke Testimony - U.S. Commentary

While buying interest was relatively subdued, stocks moved modestly higher over the course of the trading day on Tuesday. The strength on the day offset the weakness seen in the previous session, with the Dow and the S&P 500 reaching new record closing highs. The major averages gave back some ground in late-day trading but remained in positive territory.